Article
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
All News
Dr. John Cush
Tweet
Upadacitinib is now approved in European Union to treat active polyarticular juvenile idiopathic arthritis (pJIA) ages > 2yrs for those not responding to 1+ DMARDs. In the USA, UPA is approved for pJIA & juvenile PsA https://t.co/Vhx717rw5T https://t.co/hObov1Umgb
Dr. John Cush
Tweet
BMJ reports TriNetX EHR study showing GLP-1 RA use in knee OA pts was assoc w/ significantly lower cumulative TKA incidence (p<0.001). 1 year any GLP-1 RA (HR 0.90) or 3 yrs exposure (HR 0.72) signif lowered TKA 8 yrs later https://t.co/RGQJJHgLFv https://t.co/Ko7VI3ZAC0
Dr. John Cush
Tweet
Amgen announced topline results from the Phase 3 OASIZ 301 study showing the efficacy of dazodalibep in Sjögren's dz, w/ signif ESSDAI improvements at wek 48. DAZO is a CD40L antagonist fusion protein https://t.co/5QPBdZivxC https://t.co/tJvYo6TrWO
Dr. John Cush
Tweet
Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & https://t.co/ZbVwGTy0rG
Dr. John Cush
Tweet
Cluster analysis of Spanish RELES #SLE SLE cohort reveals 3 groups. C1 (n 168) was younger, w/ lupus nephritis, low C3, intensive Rx, high infx & damage. C2 (175) w/ cytopenias, serositis, APL & dsDNA(+). C3 (452) mild skin-Jts, less serologic activity & complications https://t.co/N0XLUaegWc
Dr. John Cush
Tweet
J&J announced topline results of Phase 4 STAR study where guselkumab (Tremfya) improved in axial Sxs & MRI outcomes in 411 biologic-naïve axial PsA pts, STAR is a 24 wk DBPCT of GUS (IL-23 inhib) in DMARD unresponsive pts. Endpoint was BASDAI @ wk24. https://t.co/LkqwV0zRmn https://t.co/gZuuQ4jcEf
Dr. John Cush
Tweet
Remission — believe it or not. What’s happening in rheumatology this week? Dr. Jack Cush breaks down the latest news and journal reports on RheumNow:
10-year T2T data: 82% in remission
Residual steroids don’t preserve remission
Biologics linked to lower PsA risk
GLP-1s + knee OA https://t.co/2Zf9g1Wehg
Dr. John Cush
Tweet
DERM on RheumNow PODCAST (September 2026)
The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. https://t.co/QYX9G5UFg5
Dr. John Cush
Tweet
The GLP-1 Opportunity Cost in Rheumatology
There is no doubt it is an incredibly exciting time to be tackling obesity-related diseases, like many rheumatic diseases appear to be, to some extent.
https://t.co/49EscdPOTG https://t.co/c0kSgOXZy7
Dr. John Cush
Tweet
Supervised Physiotherapy Wins after ACL Repair
The Annals of Internal Medicine has shown that chronic knee symptoms following anterior cruciate ligament reconstruction (ACLR) surgery is significantly lessened by a program of physiotherapist-supervised exercise therapy with https://t.co/8HWmkmIexr
Dr. John Cush
Tweet
The weight is off, the DMARDs are off - now what?
Sometimes it’s only when we have effective solutions that we have to think about what to do next. And when that happens, remember why we do things in the first place. In an era when weight loss is happening on scale, now we need https://t.co/MTjU5YRS5q
Dr. John Cush
Tweet
Observational study of 228 #PsA pts Rx biologics, either early (<2yrs; mean 6 mos) vs later (mean 3.6 yrs). Groups were balanced in all parameters; after 6 mos no diff in DAPSA50 or PASI75 response. Biologics work regardless of when started. https://t.co/ZCDR8l2CsI https://t.co/PHgtgZu12G
Dr. John Cush
Tweet
Treatment for Obesity and Inflammation, but at what Cost?
https://t.co/v87FxQqrAv https://t.co/Oonrexyp0F
Dr. John Cush
Tweet
Obesity & Biologic Treatment Response
Prepared for "The Obesity Imperative" campaign.
https://t.co/72TFW6BWgG https://t.co/XWFWoH2D33
Dr. John Cush
Tweet
Prednisone Primer for Patients
The Washington Post published a patient overview on "what Prednisone does to your body".
Prednisone is a double-edged drug. It has been on the market since 1955, ranks among the 40 most-prescribed US drugs, and about 10 million Americans receive
Dr. John Cush
Tweet
Worldwide the Sjögren’s disease market size was valued at approximately $1 billion USD in 2025 and is projected to reach nearly $10 billion USD by 2036 (with annual growth of 26.2% during the forecast period from 2026 to 2036). https://t.co/kxwftpIDeo https://t.co/RnEbzqFi2W
Dr. John Cush
Tweet
QD Clinic: Managing Muscle and Fat Loss with GLP-1s
Dr. David Liew, Melbourne, presents this QD Clinic as part of RheumNow's "The Obesity Imperative" campaign presented in September 2026.
https://t.co/t9uD7TGKjZ https://t.co/BzE1m04E2s
Dr. John Cush
Tweet
ARthritis & CAncer (ARCA) is Spanish retro study of 728 #RA pts w/ Hx of CA & Rx w/ biologics. W/ F/U of 11 022 yrs, new/recurrent CA was not incr (7.3/1000PYs) & = Pts Rx w/ csDMARDs (HRs 0.94; 0.73,1.21) & not incr w/ TNFi (0.94), IL-6i (1.03), CD20i (0.81), JAKi (0.6), ABA https://t.co/UUWlsaYV0Z
Dr. John Cush
Tweet
Mediterranean Diet Lowers Incident Rheumatoid Arthritis Risk
The American Journal of Clinical Nutrition has published the results of the SUN Project study, showing that long-term adherence to a Mediterranean diet (MedDiet) was associated with a substantially lower risk of https://t.co/9GhEwXuCEI
